Physician profile
Carmen E Leblanc
NPI 1477744704
$7,239.50
in general payments reported to CMS, 2019-2025
39 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,827 · 2020: $1,390 · 2021: $688 · 2022: $749 · 2023: $479 · 2024: $673 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,096.27 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $965.13 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $583.13 | 2019-2024 | Rybelsus, Ozempic |
| Medtronic Minimed, INC. | $540.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $477.24 | 2022-2025 | |
| Amgen INC. | $421.12 | 2019-2025 | Tepezza, Prolia, Evenity |
| Mannkind Corporation | $272.34 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $250.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.00 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $231.22 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $177.44 | 2019-2020 | |
| Corcept Therapeutics | $173.37 | 2019-2021 | |
| Companion Medical, INC. | $170.78 | 2019 | |
| Valeritas, INC. | $157.90 | 2019 | |
| Bigfoot Biomedical INC | $151.50 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.